Loading ......
Antibody-drug conjugate assays are only as trustworthy as the standards used to calibrate them, and conjugates make unusually demanding standards. A conventional antibody reference material has a single defined structure and a single concentration. A conjugate reference carries a distribution of payload loads, a linker that may hydrolyse during storage, and an aggregation profile that changes with handling. Without a well-characterised control, a laboratory cannot distinguish a genuine change in a test article from drift in its own method. The ADC Control Human IgG1-McMMAF was developed to fill that gap: a defined conjugate built on a human IgG1 backbone with a maleimide-coupled auristatin payload, intended as a benchmark against which both platform methods and program-specific assays can be assessed.
Figure 1. ADC Control Human IgG1-McMMAF ELISA as a Benchmark for Conjugated Antibody Quantitation.
Control materials serve several distinct purposes in conjugate bioanalysis, and a single reagent can address all of them when its properties are documented. As a calibration standard it anchors quantitation; as a positive control it verifies that a method performs as expected on the day of use; as a proficiency sample it allows laboratories to compare results across sites; and as a stability reference it reveals whether storage or shipping has degraded a conjugate preparation. Each role places different demands on characterisation, and the most common failure in conjugate method development is a control that has been characterised for one role and then used for another. A conjugate with a defined payload-to-antibody relationship, verified by orthogonal methods, can serve every role described here simultaneously, which is why programmes that establish such a material early avoid many of the comparability problems that otherwise emerge during method transfer and regulatory review. The same logic applies to platform qualification, where a shared control allows intact-conjugate methods for different molecules to be compared on a common scale.
| Control Conjugate Attributes Used in Method Qualification | Details |
| Human IgG1 Backbone | A human IgG1 framework provides a consistent antibody context for method development and matches the format of most therapeutic conjugates. Its defined Fc structure allows Fc-directed reagents to be evaluated without interference from species-specific sequence variation. |
| Maleimide-Coupled Auristatin Payload | The McMMAF payload is attached through a maleimide-based linkage to cysteine residues, producing a conjugate whose payload distribution reflects the reduction and coupling conditions used during manufacture. This chemistry is among the most widely applied in clinical conjugates, making it a relevant benchmark. |
| Intact Conjugate Concentration | Measuring the payload-bearing species tests whether a method detects conjugation rather than total protein. Comparing this value with total antibody content reveals the payload load of the reference material and provides an independent check on method specificity. |
| Platform Performance Characteristics | Because the control is a conjugate rather than a bare antibody, it can be used to qualify intact-conjugate methods across different payload-specific reagents. Consistent results across platforms indicate that a method is measuring the intended species rather than an assay-specific artefact. |
Method transfer between laboratories is where conjugate assays most often lose comparability. The receiving laboratory validates accuracy and precision using its own reagents, obtains acceptable results, and then discovers that its values differ systematically from the originating site by a margin that matters clinically. The usual causes are differences in calibration, in the recognition of payload-loaded versus stripped antibody, and in sample handling before analysis. A shared control conjugate addresses each of these by providing a common anchor: when both laboratories measure the same material and obtain the same value, their methods are demonstrably comparable, and any subsequent divergence in study samples can be attributed to the samples rather than to the assay. Proficiency testing programmes built around such a control allow a sponsor to monitor laboratory performance continuously rather than only at transfer. The same material supports reagent lot qualification, since a new lot of detection antibody can be evaluated against a fixed conjugate reference before it enters routine use. Laboratories that adopt this practice find that investigations of anomalous results become far more efficient, because the control provides an immediate answer to the question of whether the method or the sample is at fault.
| Products | Core Advantages | Primary Applicable Scenarios |
| ADC Control Human IgG1-McMMAF (ADC) ELISA Kit | A complete assay built around a defined human IgG1-McMMAF conjugate, providing both the method and the reference material needed to qualify it. The format quantifies intact conjugate with reagents that discriminate payload-bearing antibody from unconjugated carrier, and it delivers reproducible performance across laboratories and kit lots. | Platform qualification, method transfer verification, and proficiency testing for conjugate bioanalysis. |
| Intact MMAF ADC ELISA Kit | A payload-class method for intact auristatin F conjugates that can be run alongside the control to confirm that a test method and a platform method agree. Its documented performance across multiple antibody carriers makes it a practical reference for laboratories establishing new conjugate assays. | Orthogonal confirmation of intact conjugate results, cross-platform comparison, and assay bridging. |
| Rabbit Anti-MMAF polyclonal antibody | A polyclonal reagent recognising the auristatin F payload, suitable for detection in custom formats, for immunohistochemical localisation of conjugated drug or for verifying payload presence after conjugation. Its broad epitope recognition provides robust signal in applications where monoclonal reagents prove too restrictive. | Custom assay development, payload detection in tissue sections, and conjugation verification. |
| Mc-MMAF [BSA] | A hapten-carrier conjugate presenting the maleimidocaproyl auristatin payload on a bovine serum albumin scaffold, useful as an immunogen, as a coating antigen in competitive assays or as a specificity control. The defined hapten density supports reproducible antibody production and assay calibration. | Antibody generation, competitive immunoassay development, and verification of payload-specific reagent binding. |
Control materials do their most valuable work before a problem appears, establishing the conditions under which results can be trusted.
Every quantitative discipline depends on reference materials, and conjugate bioanalysis has historically been underserved by them. A defined human IgG1-McMMAF conjugate changes that situation by giving laboratories a common anchor for calibration, qualification and proficiency assessment. The ADC Control Human IgG1-McMMAF (ADC) ELISA Kit, together with an intact MMAF platform assay, an anti-MMAF polyclonal antibody and a hapten-carrier conjugate, provides the complete set of materials needed to establish and maintain conjugate methods. For laboratories building ADC capability, and for sponsors who need assurance that results from different sites are genuinely comparable, this combination supplies the metrological foundation that good bioanalysis requires.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-JY25407 | Anti-CCL2 (Carlumab)-McMMAF (ADC) ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIA-JY25410 | ADC Control Human IgG1-McMMAF (ADC) ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
Loading ......